Palisade Bio, Inc. PALI
Set alert
As of Nov 2, 10:53 AM ET
- YTD
- -52.55%
- 1 year
- -46.14%
- Open
- 1.20
- Prev close
- 1.16
- Mkt cap
- 194.31M
- Vol
- 570.04K
- Avg vol
- 2.75M
- EPS
- 0.60
- P/E
- 1.86
- Div yield
- 0.00%
More statistics
- Low
- 1.11
- High
- 1.20
- Forward P/E
- -0.19
- Beta
- 1.33
- Short ratio
- 0.29
- Inst. own
- 3.58%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.61
- 200-d avg
- 4.17
- 1y target
- 30.33
News
-
5 days ago benzinga.com
Palisade Bio Doses First Patient In Its ASCENTRA-UC Phase 2b Clinical Trial Evaluating PALI-2108 In ~204 Patients With Moderately To Severely Active Ulcerative Colitis; 12-Week Topline Results Expected In Q4 2027
PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve tolerability29 of…
5 days ago globenewswire.com
Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis
PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve tolerability
-
1 week ago benzinga.com
Palisade Bio Announces Findings Presented At United European Gastroenterology Week; Five-Patient Phase 1B Crohn’s Disease Cohort Showed 47.5% Reduction In Mean Endoscopic Disease Activity And 58.8% Reduction In Mean Fecal Calprotectin After 14 Days; Phase 2b ASCENTRA-UC Study Is Enrolling; Phase 2a Crohn’s Disease Study Being Initiated
linical and translational findings presented in one oral presentation and three moderated posters at United European Gastroenterology (UEG) Week 2026, held October 17–20 in Barcelona, Spain. The…
1 week ago globenewswire.com
Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026
Five-patient Phase 1b Crohn's disease cohort showed a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in mean fecal calprotectin after 14 days
-
2 weeks ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Palisade Bio (NASDAQ:PALI) with a Buy and maintains $7 price target.
-
3 weeks ago benzinga.com
Palisade Bio Highlights PALI-2108 Clinical And Translational Findings In 5 ACG 2026 Presentations
Five presentations connect targeted intestinal exposure and sustained systemic drug exposure with PDE4 target engagement and early clinical activity, supporting ongoing Phase 2 developmentTwo…
3 weeks ago globenewswire.com
Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026
Five presentations connect targeted intestinal exposure and sustained systemic drug exposure with PDE4 target engagement and early clinical activity, supporting ongoing Phase 2 development Two…
-
3 weeks ago benzinga.com
Raymond James Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $6
Raymond James analyst Thomas Deal initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $6.
1 month ago defenseworld.net
Palisade Bio, Inc. (NASDAQ:PALI) Stock Has Average Target Price of $9.83 According to Analysts
Palisade Bio, Inc. (NASDAQ: PALI - Get Free Report) has been given a consensus rating of "Buy" by the ten ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research…
-
1 month ago benzinga.com
Palisade Bio To Present Four Presentations At United European Gastroenterology Week 2026 For Its PALI-2018 Program
Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic…
1 month ago globenewswire.com
Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026
Oral presentation to highlight early endoscopic improvement and evidence of PDE4 target engagement in fibrostenotic Crohn's disease
1 month ago defenseworld.net
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s
Palisade Bio (NASDAQ: PALI) said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn's disease after completing its Phase I program. Chief…
1 month ago marketbeat.com
Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn's
Palisade Bio NASDAQ: PALI said it is advancing its lead drug candidate, PALI-2108, into Phase II studies for ulcerative colitis and Crohn's disease after completing its Phase I program.
-
1 month ago benzinga.com
Palisade Bio Receives Health Canada's Clearance For Its Clinical Trial Application For ASCENTRA-UC Trial Of PALI-2108 To Treat Severely Active Ulcerative Colitis
Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic
1 month ago globenewswire.com
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108 Primary efficacy results from approximately 204 patients with moderately to severely active…
-
1 month ago benzinga.com
HC Wainwright & Co. Reiterates Buy on Palisade Bio, Maintains $7 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Palisade Bio (NASDAQ:PALI) with a Buy and maintains $7 price target.
-
1 month ago benzinga.com
Palisade Bio Receives FDA Clearance For Its Investigational New Drug Application For PALI-2108 To Treat Crohn's Disease; First Participant Enrollment Anticipated In Q1 Next Year
Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation prodrugs for patients living with inflammatory and fibrotic…
1 month ago globenewswire.com
Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn's Disease, Expanding Phase 2 Development Across IBD
ASCENTRA-CD expected to enroll approximately 60 patients with moderate to severe Crohn's disease First patient dosing targeted for Q1 2027; primary efficacy readout (Week 12 endoscopic response)…
1 month ago globenewswire.com
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Presentation scheduled for September 23, 2026 at 1:00 PM ET Access the webcast here Denver, CO, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a…
1 month ago seekingalpha.com
Palisade Bio, Inc. (PALI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Palisade Bio, Inc. (PALI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago benzinga.com
ServiceTitan, Braze, Target Hospitality And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
U.S. futures were mixed; ServiceTitan plunged 16.7% on weak Q3 guidance, while Mind Technology, Braze and others also fell premarket.
2 months ago globenewswire.com
Palisade Bio to Participate in Upcoming Investor Conferences
Denver, CO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation prodrugs for…
2 months ago defenseworld.net
Brokerages Set Palisade Bio, Inc. (NASDAQ:PALI) Price Target at $9.00
Palisade Bio, Inc. (NASDAQ: PALI - Get Free Report) has received a consensus rating of "Buy" from the ten ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst…
-
2 months ago benzinga.com
Palisade Bio Q2 EPS $(0.05), Inline, Sales $500.000K
Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 91.38 percent increase over losses of $(0.58) per share from the same…
2 months ago globenewswire.com
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD) Enrollment of first…
3 months ago benzinga.com
Palisade Bio Draws Bullish Call, Lead IBD Drug Advances Toward Phase 2
Oppenheimer on Thursday initiated coverage of Palisade Bio Inc. (NASDAQ:PALI) , saying the stock offers investors an attractive way to gain exposure to the fast-growing inflammatory bowel disease…
3 months ago benzinga.com
This Signet Jewelers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top analysts change outlook on top names. See all changes and ratings on our analyst ratings page. Check out what analysts think about SIG stock.
-
3 months ago benzinga.com
Oppenheimer Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $8
Oppenheimer analyst Leland Gershell initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $8.
3 months ago globenewswire.com
Palisade Bio to Participate in the Leerink Partners Therapeutics Forum
Management to participate in investor meetings on July 14-15 in Boston Denver, CO, July 10, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), a clinical-stage…
3 months ago seekingalpha.com
Palisade Bio: A Unique MoA Targeting The UC And Crohn's Disease Markets
Palisade Bio offers a speculative early-stage opportunity, advancing PALI-2108, a gut-restricted PDE4 inhibitor for UC and Crohn's disease. PALI-2108's Phase 1 trials showed favorable safety, target…
-
4 months ago benzinga.com
Palisade Bio Says FDA Clears IND Application For PALI-2108, Enabling Initiation Of Global Phase 2 ASCENTRA-UC Clinical Trial In Patients With Active Ulcerative Colitis
ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and EuropeFirst patient enrollment anticipated in the second half of 2026;…
4 months ago globenewswire.com
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe
4 months ago globenewswire.com
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors
Board strengthened with extensive biotechnology leadership, strategic transactions and capital markets expertise Company continues to build on PALI-2108 clinical progress as it advances toward Phase…
-
4 months ago benzinga.com
Palisade Bio To Present Novel PDE4 Inhibitor Strategy For Fibrostenotic Crohn's Disease At NYAS Fibrosis Symposium
Presentation to highlight fibrostenotic Crohn's disease biology and the potential of a locally bioactivated PDE4 inhibitor prodrug approachDenver, CO, June 09, 2026 (GLOBE NEWSWIRE) -- Palisade Bio,…
5 months ago benzinga.com
Verra Mobility, Zscaler, Box And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Stock futures rise on Wednesday, with Verra Mobility's shares plunging 45% after Avis Budget Group terminated its agreement with the company. Other stocks moving lower in pre-market trading include…
-
5 months ago benzinga.com
Palisade Bio Q1 EPS $(0.05) Misses $(0.04) Estimate
Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 89.36 percent increase over losses of $(0.47)…
-
6 months ago benzinga.com
Palisade Bio Presents Additional Phase 1a/B Analyses Of PALI-2108, Including Delayed Ileocolonic Activation, High Tissue-To-Plasma Exposure, And Sustained Steady-State Concentrations Of Active Metabolite Above IC90, At Digestive Disease Week 2026
Data demonstrate colon tissue PDE4/cAMP pathway modulation and sustained active metabolite exposure above IC90 across the dosing intervalSteady-state pharmacokinetic findings provide mechanistic…
6 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
6 months ago benzinga.com
Palisade Bio's Data From Its Lead Program, PALI-2108, Selected For Poster Presentation At Digestive Disease Week 2026
Poster presentation scheduled for Tuesday, May 5th at 12:30 PM CDTDenver, CO, April 16, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), a clinical-stage…
-
6 months ago benzinga.com
Wolfe Research Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $7
Wolfe Research analyst Andy Chen initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outperform rating and announces Price Target of $7.
-
7 months ago benzinga.com
Palisade Bio Announces Topline Data From Phase 1b Clinical Study Evaluating PALI-2108, Once-Daily Oral PDE4 Inhibitor Prodrug To Be Selectively Bioactivated In Ileum And Colon, In Patients With FSCD
PALI-2108 demonstrated favorable safety and tolerability with no serious adverse events after two weeks of treatment in a difficult-to-treat population Phase 1b data demonstrate endoscopic…
-
7 months ago benzinga.com
HC Wainwright & Co. Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $7
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $7.
8 months ago benzinga.com
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
-
8 months ago benzinga.com
Stifel Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $5
Stifel analyst Alex Thompson initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $5.
-
8 months ago benzinga.com
Palisade Bio Announces Presentation Of New Translational Data For PALI-2108 At 21st Congress Of ECCO In Stockholm
Phase 1b translational data demonstrate localized ileocolonic target engagement, suppression of inflammatory and fibrotic gene programs, and early clinical response within seven daysEncouraging…
-
9 months ago benzinga.com
Palisade Bio Two Abstracts Selected For Poster Presentation At Two Premier International Inflammatory Bowel Diseases Meetings
Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted…
-
9 months ago benzinga.com
B. Riley Securities Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $7
B. Riley Securities analyst William Woods initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $7.
-
9 months ago benzinga.com
Palisade Bio Secures Up To $500K Strategic Investment From The Crohn's & Colitis Foundation, To Advance PALI-2108 For Ulcerative Colitis And Fibrostenotic Crohn's Disease
PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing significant unmet needs in ulcerative colitis (UC) and…
10 months ago benzinga.com
Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December
Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December
-
10 months ago benzinga.com
Clear Street Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $12
Clear Street analyst Kaveri Pohlman initiates coverage on Palisade Bio (NASDAQ:PALI) with a Buy rating and announces Price Target of $12.